NEW YORK (GenomeWeb News) - Transgene said today that the French Agency for Industrial Innovation has awarded it €25 million ($32.7 million) to participate in a pharmacogenomics project called ADNA (Advanced Diagnostics and New therapeutic Approaches).
ADNA includes four partners -- Transgene, bioMerieux, Genethon, and GenoSafe -- and aims to improve personalized medicine in the fields of cancer, infectious diseases, and rare genetic diseases.
According to a statement from Transgene, the “core” of the program will be the development and validation of biomarkers to help guide the prescription of new treatments to those patients most likely to benefit from them.
The funding is subject to European Commission approval, which is expected in the second quarter of 2007, Transgene said.
The funding includes grants of €17.8 million and loans of €7.2 million refundable only in the case of success.